Andrea L Cheville1, Naveen S Murthy2, Jeffrey R Basford3, Peter S Rose4, Kenny Tran3, Thomas P Pittelkow3, Michael D Ringler2. 1. Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN. Electronic address: cheville.andrea@mayo.edu. 2. Department of Radiology, Mayo Clinic, Rochester, MN. 3. Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN. 4. Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To distinguish which patients with bone metastases are at risk for near-term disablement in order to assist clinicians in assessing the appropriateness of referrals for rehabilitation services. DESIGN: Prospective cohort study. SETTING: National Cancer Institute-designated comprehensive cancer center imbedded in a tertiary medical center. PARTICIPANTS: Data were collected from members (n=78) of a patient cohort (N=311) with stage IIIB or IV non-small-cell lung cancer or extensive-stage small-cell lung cancer who developed new or progressive imaging-confirmed bone metastases during the 2-year course of the study. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Functional capabilities were assessed at 3- to 4-week intervals over the study's 2-year duration with the Activity Measure for Post-Acute Care Computer Adaptive Testing. RESULTS: Seventy-eight participants developed new or progressive bone metastases during the study. Most were men, and 83% had non-small-cell lung cancer. Metastases were most frequently located in the ribs (n=62), pelvis (n=49), or the thoracic (n=60) and lumbar spine (n=44). While neither the number of bone metastases nor their specific location was associated with near-term changes in patient mobility, their association with pain or a focal neurologic deficit was strongly associated with large declines in mobility. Similarly, patients whose imaging studies revealed new metastases and the expansion of established metastases were more likely to lose mobility. CONCLUSIONS: The total burden, specific locations, and overall distribution of bone metastases did not predict disablement. Patients with lung cancer-associated bone metastases are at markedly increased risk for declining mobility when their metastases are expanding in size and increasing in number, or are associated with pain or with new neurologic deficits.
OBJECTIVE: To distinguish which patients with bone metastases are at risk for near-term disablement in order to assist clinicians in assessing the appropriateness of referrals for rehabilitation services. DESIGN: Prospective cohort study. SETTING: National Cancer Institute-designated comprehensive cancer center imbedded in a tertiary medical center. PARTICIPANTS: Data were collected from members (n=78) of a patient cohort (N=311) with stage IIIB or IV non-small-cell lung cancer or extensive-stage small-cell lung cancer who developed new or progressive imaging-confirmed bone metastases during the 2-year course of the study. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Functional capabilities were assessed at 3- to 4-week intervals over the study's 2-year duration with the Activity Measure for Post-Acute Care Computer Adaptive Testing. RESULTS: Seventy-eight participants developed new or progressive bone metastases during the study. Most were men, and 83% had non-small-cell lung cancer. Metastases were most frequently located in the ribs (n=62), pelvis (n=49), or the thoracic (n=60) and lumbar spine (n=44). While neither the number of bone metastases nor their specific location was associated with near-term changes in patient mobility, their association with pain or a focal neurologic deficit was strongly associated with large declines in mobility. Similarly, patients whose imaging studies revealed new metastases and the expansion of established metastases were more likely to lose mobility. CONCLUSIONS: The total burden, specific locations, and overall distribution of bone metastases did not predict disablement. Patients with lung cancer-associated bone metastases are at markedly increased risk for declining mobility when their metastases are expanding in size and increasing in number, or are associated with pain or with new neurologic deficits.
Authors: Stephen M Haley; Patricia L Andres; Wendy J Coster; Mark Kosinski; Pengsheng Ni; Alan M Jette Journal: Arch Phys Med Rehabil Date: 2004-04 Impact factor: 3.966
Authors: Wendy J Coster; Stephen M Haley; Patricia L Andres; Larry H Ludlow; Tamara L Y Bond; Peng-Sheng Ni Journal: Med Care Date: 2004-01 Impact factor: 2.983
Authors: Nicole L Stout; Justin C Brown; Anna L Schwartz; Timothy F Marshall; Anna M Campbell; Larissa Nekhlyudov; David S Zucker; Karen M Basen-Engquist; Grace Campbell; Jeffrey Meyerhardt; Andrea L Cheville; Kelley R Covington; Jennifer A Ligibel; Jonas M Sokolof; Kathryn H Schmitz; Catherine M Alfano Journal: Cancer Date: 2020-03-25 Impact factor: 6.860
Authors: Jonathan M Hagedorn; Thomas P Pittelkow; Christine L Hunt; Ryan S D'Souza; Tim J Lamer Journal: J Pain Res Date: 2020-12-07 Impact factor: 3.133